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PodocyteRenal ubiquitin C-terminal hydrolase L1 (UCHL1) is upregulated in a subset of human glomerulopathies, includ-
ing focal segmental glomerulosclerosis (FSGS), where it may serve to promote ubiquitin pools for degradation of
cytotoxic proteins. In the present study, we testedwhether UCHL1 is expressed in podocytes of amousemodel of
ACTN4-associated FSGS. Podocyte UCHL1 protein was detected in glomeruli of K256E-ACTN4pod+/UCHL1+/+
mice.UCHL1+/−micewere intercrossedwith K256E-ACTN4pod+mice andmonitored for features of glomerular
disease. 10-week-old K256E-ACTN4pod+/UCHL1−/− mice exhibited signiﬁcantly ameliorated albuminuria,
glomerulosclerosis, tubular pathology and blood pressure. Interestingly, while UCHL1 deletion diminished both
tubular and glomerular apoptosis, WT1-positive nuclei were unchanged. Finally, UCHL1 levels correlated posi-
tively with poly-ubiquitinated proteins but negatively with K256E-α-actinin-4 levels, implying reduced
K256E-α-actinin-4 proteolysis in the absence of UCHL1. Our data suggest that UCHL1 upregulation in ACTN4-
associated FSGS fuels the proteasome and that UCHL1 deletion may impair proteolysis and thereby preserve
K256E/wt-α-actinin-4 heterodimers, maintaining podocyte cytoskeletal integrity and protecting the glomerular
ﬁltration barrier.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
α-Actinin-4 cross-links and bundles F-actin [1,2] regulating key
cytoskeletal dependent processes [3,4]. Mutations in the ACTN4
gene are associated with a familial autosomal dominant form of
focal segmental glomerulosclerosis (FSGS) [5–7]. FSGS-linked muta-
tions in the ACTN4 gene, such as the K255E mutation (K256E in
mice), expose a third actin-binding site, increase its afﬁnity for actin
and promote α-actinin-4/actin aggregate formation in podocytes [5,
8–10]. While the K256E-α-actinin-4 protein can homodimerize, it can
also heterodimerize with wt-α-actinin-4 such that wt-α-actinin-4
bound to the mutant form can be detected in K256E-α-actinin-4/actin
aggregates. While these aggregates undergo poly-ubiquitination and
proteasomal degradation thereby reducing the overall expression levels
of K256E-α-actinin-4, over time, these become supersaturated andanada.
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).“choke” the ubiquitin–proteasome system (UPS) thereby leading to
their accumulation, as demonstrated in vitro [10,11]. Mice with
podocyte-speciﬁc overexpression of K256E-α-actinin-4 develop al-
buminuria, podocyte foot process (FP) effacement and FSGS lesions
[12]. However the precise subcellular mechanism(s) that underlie
α-actinin-4/actin aggregate-dependent podocyte injury remain in-
completely elucidated.
Podocyte ubiquitin C-terminal hydrolase L1 (UCHL1) is upregulated
in a subset of human glomerulopathies, including primary FSGS [13].
Among an array of other ubiquitin (Ub)-regulating functions is a sal-
vage function wherein the UCHL1 enzyme hydrolyzes small C-
terminal adducts from Ub [14,15]. UCHL1 also binds and stabilizes
mono-Ub in vitro and maintains intracellular Ub pools [16]. Signiﬁcant
UCHL1 expression has been reported in podocytes of patients with glo-
merular diseases, such as IgA nephropathy, FSGS etc. [13,17,18]. UCHL1
upregulation upon podocyte injury may serve to generate/promote
availability of free monomeric Ub for poly-ubiquitination and degrada-
tion of aggregates/cytotoxic proteins via the UPS. Interestingly, UCHL1
deﬁciency in gracile axonal dystrophy (gad) mice, which have an in-
frame deletion comprising exons 7 and 8 of the UCHL1 gene and no
detectable UCHL1 protein, is linked to the accumulation of cytotoxic
proteins and impaired protein turnover in neurons [19]. Similarly,
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cells [20]. Despite conﬂicting ﬁndings for UCHL1 in neurons, recent
ﬁndings in the kidney, speciﬁcally in a rat model of membranous ne-
phropathy, demonstrate that UCHL1 upregulation coincides with
poly-ubiquitinated protein accumulation and UPS activity decline.
Pharmacological inhibition of UCHL1 in thismodel restoresUPS activity,
decreases poly-ubiquitinated proteins and ameliorates the overall glo-
merular pathology [21]. Taken together these data suggest a maladap-
tive role for UCHL1 in glomerular disease.
Based on these ﬁndings, we propose that UCHL1 induction in the
presence of K256E-α-actinin-4/actin aggregation is maladaptive for
protein turnover. In the present study, we tested the hypothesis that
UCHL1 deletion in amousemodel of ACTN4-associated FSGS reduces in-
dications of ﬁltration barrier injury and glomerular lesions.2. Materials and methods
2.1. Mice studies
Mice were housed at the Animal Care facility at the University of
Ottawa. Protocols were approved and undertaken according to the
Canadian Council on Animal Care guidelines. Euthanasia was per-
formed by anesthetizing mice by inhalation of isoﬂurane and perfu-
sion with 20 ml PBS through the left ventricle.2.2. Immunoﬂuorescence/immunohistochemistry of parafﬁn-embedded
sections
Harvested kidneys were incubated in a 4% paraformaldehyde/PBS
solution for 24 h and processed for parafﬁn embedding. Kidney sections
were rehydrated through graded ethanol solutions (100%, 90% and 70%;
v:v), boiled in 10 mM/1 mM/0.05% Tris/EDTA/Tween-20 pH 9.0 or
sodium citrate 0.01 M pH 6.0 and incubated with 0.3% H2O2 in
MeOH. For UCHL1 immunoﬂuorescence, 2 μm sections were incubat-
ed with mouse anti-PGP9.5 1:400 (Abcam, Toronto, ON) and anti-α-
actinin-4 1:200 (Abcam, Toronto, ON) o/n at 4 °C, then incubated
with secondary Cy3-donkey anti-mouse 1:100 and Alexa Fluor 488-
donkey anti-rabbit 1:100 (Jackson ImmunoResearch Laboratories,
West Grove, PA) for 1 h at room temperature. For UCHL1 immunohisto-
chemistry, 5 μmsectionswere incubatedwithmouse anti-UCHL1 1:600
(Novus Biologicals, Oakville, ON) o/n at 4 °C, then processed ac-
cording to the ImmPRESS Reagent Anti-mouse Ig (rat adsorbed)
Kit (Vector Laboratories, Burlingame, CA) and ﬁnally processedwith di-
aminobenzidine/H2O2 (Sigma-Aldrich, Oakville, ON). Cortical renal sec-
tions were visualized blinded with a Zeiss Axio Imager A1 microscope.2.3. K256E-ACTN4pod+/UCHL1−/− mice
The fourth exon of themurineUCHL1 genewas replaced by inserting
a neomycin resistance gene with a selectable marker for embryonic
stem cells. Mice were established on 129v/J and C57Bl/6 genetic back-
grounds (Gray and Coulombe, submitted). UCHL1+/− mice were
intercrossed with K256E-ACTN4pod+ mice [12]. K256E-ACTN4pod+
mice were maintained on a C3H background. The pups and littermate
controls used for this study were of mixed backgrounds, including
129v/J, C57Bl/6 and C3H. Genotypingwas performed by PCR of genomic
DNA isolated from ear snips of 3-week-oldmice. ForUCHL1: 5′-CTGGAC
CACCATCTGCTTAC-3′ (forward primer), 5′-CAGCTTGTCTTGGTTGTTGG-
3′ (wild type reverse primer) and 5′-AAGCGAAGGAGCAAAGCTGC-3′
(UCHL1−/− reverse primer). For K256E-ACTN4pod+: 5′-GAGAAAGA
ACTGTTAACGGG-3′ (forward primer) and 5′-AGTTAGTCGCCCATGC
TTC-3′ (reverse primer).Micewere obtained at the expectedMendelian
ratio.2.4. RNA isolation and quantitative PCR
Cortical kidney tissue was homogenized with a COE Capmixer and
processed for RNA isolation with the RNeasy Mini Kit (Qiagen, Toronto,
ON) and converted to cDNAwith the High Capacity cDNA Reverse Tran-
scriptionKit (Applied Biosystems, Burlington,ON). qPCRwasperformed
using the Real-Time qPCR Master Mix–SYBR Advantage qPCR Premix
(Clontech, Mountainview, CA). UCHL1 primers were designed to span
exons 4–6 of the UCHL1 gene. UCHL1 forward primer (439F): 5′-TGGT
ACCATCGGGTTGATCC-3′ and reverse primer (723R): 5′-TGGTTCACTG
GAAAGGGCAT-3′. Control RNA from rodent, obtained from the TaqMan
Rodent GAPDH Control Reagents, served as a global control (Applied
Biosystems, Burlington, ON). GAPDH served as a loading control using
primers from the TaqMan Rodent GAPDH Control Reagents (Applied
Biosystems, Burlington, ON).
2.5. Albumin/creatinine ratios
Spot urine was obtained from mice at 4 and 10 weeks of age.
Albumin concentration was measured by ELISA (Bethyl Laboratories,
Montgomery, TX) and normalized to creatinine content measured by
the Creatinine Companion Kit (Exocell, Philadelphia, PA).
2.6. Plasma creatinine
At sacriﬁce, mouse blood was collected using heparinized syringes.
Blood samples were centrifuged at 5000 rpm for 10 min at 4 °C and
the supernatant was collected. Mouse plasma was stored at −80 °C
for subsequent use. For plasma creatinine determination,mouse plasma
was analyzed commercially by IDEXX (IDEXX Labs, Toronto, ON).
2.7. Kidney histology
Kidneyswere dissected, cut into b0.5 cmportions and incubated in a
4% paraformaldehyde/PBS solution for 24 h before being processed for
parafﬁn embedding. Parafﬁn-embedded blocks were cut into 4–5 μm
sections and stained with periodic acid-Schiff (PAS) stain. Analysis of
glomerulosclerosis was performed using a Zeiss Axio Imager A1 micro-
scope. Glomeruli were subdivided into categories based upon the pro-
portion of mesangial matrix occupying the glomerular tuft (healthy,
25–40% matrix; segmental sclerosis, 40–75% matrix; and global sclero-
sis, N75% matrix). The relative difference between the Bowman's cap-
sule area and the glomerular tuft area was computed using Alpha
Innotech software andwas determined by subtracting the total glomer-
ular tuft area from the total Bowman's capsule area. Tubulointerstitial
inﬂammation was scored from 0 to 3, where 0, healthy tubules with
few interstitial cells; 1, healthy tubules with some interstitial cells
(b10% of ﬁeld); 2, tubulointerstitial inﬂammation (10–25% of ﬁeld)
with some tubular damage; and 3, signiﬁcant tubulointerstitial inﬂam-
mation (25–50% of ﬁeld) with some tubular invasion and destruction.
Renal sections were analyzed in a blinded fashion. For electron micros-
copy, dissected kidneys were incubated in 2.7% glutaraldehyde/PBS,
rinsed in a sodium cacodylate buffer, followed by OsO4, water, uranyl
acetate and dehydrated with ethanol and acetone and embedded in
spur resin. Sections were visualized with a Hitachi 7100 transmission
electron microscope. The number of podocyte FP per glomerular base-
mentmembrane (GBM) length andGBM thicknesswas analyzed as pre-
viously described [22,23], using Axiovision software.
2.8. Systolic blood pressure
Tail cuff plethysmography (BP-2000 Visitech Sytems, Apex, NC)
was used to measure systolic blood pressure. Mice were trained at
5 weeks of age and baseline measurements were taken at 6 weeks
of age. Blood pressure was assessed at 7 and 10 weeks of age. Mea-
surements were collected over 3–5 consecutive days.
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Undifferentiated conditionally immortalized human podocytes
(passage b15) were cultured at 33 °C on collagen-I-coated dishes
supplemented with RPMI-1640 containing 10% fetal bovine serum,
100 U/ml penicillin, 100 μg/ml streptomycin (InvivoGen, San Diego,
CA) and 10 U/ml γ-interferon (Sigma-Aldrich, Oakville, ON). For dif-
ferentiation, podocytes were thermoshifted to 37 °C and cultured on
collagen-I-coated dishes supplemented with RPMI-1640 containing
2% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin
(InvivoGen, San Diego, CA). Podocytes were differentiated on 10 cm
dishes at a cell density of 1 × 105 cells per dish, for a minimum of
10 days. COS7 cells were cultured in DMEM containing 10% fetal
bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin
(InvivoGen, San Diego, CA). Cells were grown on 10 cm dishes at a
starting cell density of 2 × 105 cells per dish and harvested after a
maximum of 2 days during which appropriate treatments took place.
2.10. Adenoviral infection
At day 10 post-thermoshift or 24 h after seeding, differentiated
podocytes or COS7 cells, respectively, were incubated with adenovi-
rus atappropriate multiplicity of infections (MOI) to yield overex-
pression of GFP, WT- and K256E-α-actinin-4 as previously
described [8]. The adenoviral infection was incubated for 24, 48 or
72 h where appropriate.
2.11. UCHL1 siRNA knockdown
UCHL1 siRNA oligonucleotides (Qiagen, Toronto, ON) and scrambled
oligonucleotides (Santa Cruz Biotechnology, Santa Cruz, CA) were
incubated in serum-free RPMI-1640 with HiPerfect transfection re-
agent (Qiagen, Toronto, ON), as per the manufacturer's instructions,
for 10 min at room temperature to allow complex formation. Com-
plexes were added to differentiated conditionally immortalized
human podocytes seeded on 10 cm dishes. Complexes were incubated
for 72 h at which time cells were harvested and processed for western
immunoblotting. For co-transfection/infection, cells were incubated
with the appropriate siRNA for 24 h at which time the appropriate ade-
novirus was administered (without changing themedia). Cells were in-
cubated for an additional 48 h, for a total of 72 h.
2.12. Protein isolation
Cortical kidney tissue was homogenized with a COE Capmixer
and resuspended in a RIPA lysis buffer (150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris pH 8.0),
supplemented with a protease inhibitor cocktail 1:100 (Sigma-
Aldrich, Oakville, ON). Glomeruli were isolated from kidney as previ-
ously described [24]. Differentiated conditionally immortalized
human podocytes and COS7 cells were washed once with PBS and
scraped in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
ethyleneglycol tetraacetate, 1 mM ethylenediaminetetraacetic acid,Fig. 1.UCHL1 is expressed in glomeruli of K256E-ACTN4pod+/UCHL1+/+mice. (A) Immunohist
of 10-week-oldK256E-ACTN4pod+/UCHL1+/+mice (n=3per group). Aminimumof 20 glome
positive glomerular cells in K256E-ACTN4pod+/UCHL1+/+ mice (p b 0.001 vs. nonTG/UCH
ACTN4pod+/UCHL1+/+ mice, as determined by double immunoﬂuorescence using antibodies
of 20 glomeruli were analyzed per mouse. Magniﬁcation, 630×. (D–E) UCHL1 induction in glo
of glomerular lysates (p b 0.001 vs. nonTG/UCHL1+/+mice) (n = 3–4 per group). (F) Repres
K256E-ACTN4pod+/UCHL1+/+ mice as compared to nonTG/UCHL1+/+ mice (n = 3 per grou
(20, 50 and 100) for 24 h, illustrate increased UCHL1 protein levels as compared to WT-α-ac
depicting UCHL1 protein levels, as determined by densitometry, that are signiﬁcantly increased
pressing COS7 cells at equivalentMOI (p b 0.01 forMOI= 20, p b 0.001 forMOI=50 and p b 0.
(MOI=30) and subjected to differential centrifugation shownodifferences inUCHL1protein le
Actin served as a loading control for all immunoblots. UCHL1mRNA levelswere not signiﬁcantly
determined by qPCR. UCHL1 mRNA levels were normalized to GAPDH mRNA (n = 3 per group1% Triton X-100, 0.5% Nonidet P-40) and RIPA lysis buffer (150 mM
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM
Tris pH 8.0), respectively, and supplemented with protease inhibitor
cocktail 1:100 (Sigma-Aldrich, Oakville, ON). Protein lysates were incu-
bated at 4 °C for 10 min. Extracted proteins (60 μg of renal lysates and
20 μg of glomerular and cellular lysates) were processed for SDS-PAGE
on appropriate percentage gels.
2.13. Immunoblotting
Immunoblotting of renal tissue was performed using rabbit anti-Ub
(Cedarlane, Burlington, ON) or rabbit anti-UCHL1 1:1000 (Millipore,
Darmstadt, Germany) or rabbit anti-HA 1:125 (Invitrogen, Burlington,
ON) o/n at 4 °C. For cells, immunoblotting was performed using
mouse anti-HA7 1:10,000 (Sigma-Aldrich, Oakville, ON) for 1 h at room
temperature and rabbit anti-UCHL1 1:1000 (Millipore, Darmstadt,
Germany) o/n at 4 °C. β-Actin served as a loading control for all im-
munoblots, using mouse anti-β-actin 1:10,000 (Sigma-Aldrich,
Oakville, ON) for 1 h at room temperature. Secondary antibodies in-
cluded HRP-goat anti-rabbit 1:10,000 (Jackson ImmunoResearch
Laboratories, West Grove, PA) and HRP-goat anti-mouse 1:10,000
(Jackson ImmunoResearch Laboratories, West Grove, PA), and
were added appropriately following primary antibody incubations,
for 1 h at room temperature. Densitometry of western blots was
computed using Alpha Innotech software.
2.14. Immunoﬂuorescence on frozen sections
Dissected kidneys were frozen in a Tissue Tek O.C.T. compound
(Sakura Finetek, Torrance, CA) in 2-methylbutane. Embedded kidney tis-
sues were sectioned at 10 μm. For immunoﬂuorescence, sections were
dried, washed with PBS and blocked with 10% donkey serum
(Jackson ImmunoResearch Laboratories, West Grove, PA) in 1% BSA/PBS
for 1 h at room temperature. Sections were incubated with rabbit anti-
WT1 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA) o/n at 4 °C.
After washing with PBS, sections were incubated with Alexa Fluor
488-donkey anti-rabbit 1:500 (Jackson ImmunoResearch Laboratories,
West Grove, PA) for 1 h at room temperature. WT1-positive nuclei
were quantiﬁed by counting the total number per glomerulus
using Axiovision software. Sections were visualized with a Zeiss
Axioskop 2 MOT epiﬂuorescence microscope (Zeiss, Germany).
2.15. TUNEL
Dissected kidneys were incubated in a 4% paraformaldehyde/PBS
solution for 24 h before being processed for parafﬁn embedding. Kid-
neys were cut into 4–5 μm sections and stained according to the
TUNEL Apoptosis Detection Kit for parafﬁn-embedded tissue sec-
tions, biotin-labeled POD protocol (GenScript, Piscataway, NJ). Apo-
ptosis was quantiﬁed by counting the number of TUNEL-positive
tubular nuclei per renal section and the total TUNEL-positive glo-
merular nuclei per glomerular section. Sections were analyzed in a
blinded manner.ochemistry reveals extensive UCHL1 induction in glomeruli (likely podocytes, arrowheads)
ruli were analyzed permouse.Magniﬁcation, 640×. (B) Graphdepicting increasedUCHL1-
L1+/+ mice). (C) UCHL1 induction in glomeruli is conﬁrmed in podocytes of K256E-
against UCHL1 and the podocyte marker α-actinin-4 (n = 3–4 per group). A minimum
meruli of K256E-ACTN4pod+/UCHL1+/+mice is conﬁrmed by western immunoblotting
entative immunoblot showing elevated poly-ubiquitinated protein levels in 10-week-old
p). (G) COS7 cells overexpressing HA-tagged K256E-α-actinin-4, infected at various MOI
tinin-4 and uninfected controls. β-Actin served as a loading control (n = 3). (H) Graph
in K256E-α-actinin-4 overexpressing COS7 cells as compared toWT-α-actinin-4 overex-
01 forMOI= 100). (I) Humanpodocytes overexpressingGFP,WT- and K256E-α-actinin-4
vels. A representative immunoblot using anti-HA conﬁrms the infection efﬁcacy (n=3).β-
different in renal (J) and glomerular (K) lysates of K256E-ACTN4pod+/UCHL1+/+mice as
).
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Differentiated conditionally immortalized human podocytes were
scraped in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
ethyleneglycol tetraacetate, 1 mM ethylenediaminetetraacetic acid, 1%
Triton X-100, 0.5% Nonidet P-40) supplementedwith protease inhibitor
cocktail at 1:100 (Sigma-Aldrich, Oakville, ON). A volume of the whole
cell lysate was reserved for the input (I) and for protein determination.
The remaining volumewas centrifuged for 15min at 13,000 rpm to iso-
late Triton-soluble (TS) and Triton-insoluble (TI) fractions. The superna-
tant (the TS fraction) was collected and the pellet (the TI fraction) was
resuspended in an equal volume of lysis buffer. 20 μg of protein
was resolved by SDS-PAGE. Densitometry was computed as de-
scribed above and by normalizing HA/β-actin for all fractions before
normalizing TS/TI.
2.17. Statistics
Values are expressed as the mean or mean percentage ± SE. Sta-
tistical comparisons were carried out by one-way ANOVA followed
by either Bonferroni or Newman–Keuls post-tests or with a t-test
for analyses including exclusively two groups. For albuminuria, a
longitudinal analysis using a random coefﬁcient model and a linear
trend for the mean response statistical test was performed.
3. Results
3.1. UCHL1 is expressed in glomeruli of K256E-ACTN4pod+/UCHL1+/+
mice
UCHL1 induction is associated with podocyte injury in a subset of
glomerulopathies, including FSGS [13,17,18]. While healthy podocytes
express little UCHL1, podocyte injury may trigger UCHL1 upregulation
for degradation of cytotoxic proteins. We veriﬁed UCHL1 expression in
glomeruli of mice with ACTN4-associated FSGS. Immunohistochemistry
revealed 3 ± 2 UCHL1-positive cells per glomerulus in nonTG/
UCHL1+/+ mice which was signiﬁcantly increased to 7 ± 4
UCHL1-positive cells per glomerulus in K256E-ACTN4pod+/
UCHL1+/+ albuminuric mice (p b 0.001) (Fig. 1A and B). To verify
podocyte-speciﬁc expression of UCHL1, a double immunoﬂuores-
cence staining procedure was performed using appropriate antibod-
ies against UCHL1 and the podocyte marker α-actinin-4. Indeed,
podocyte-speciﬁc expression of UCHL1 was detectable in glomeruli
of K256E-ACTN4pod+/UCHL1+/+ mice. UCHL1 expression appeared
mainly nuclear but was occasionally detectable in podocyte cytoplasm
(Fig. 1C). Immunoblotting of glomerular lysates also revealed increased
UCHL1 protein levels, associated with increased poly-ubiquitinated
proteins, in K256E-ACTN4pod+/UCHL1+/+ glomeruli as compared to
nonTG/UCHL1+/+ mice (p b 0.001) (Fig. 1D–F). We next tested
whether increases in UCHL1 were observable in cell lines expressing
the K256E-α-actinin-4mutant.We infected COS7 cells with adenovirus
containing constructs forWT- and K256E-α-actinin-4 at a range of MOI
and found that the levels of WT- or K256E-α-actinin-4 increased as
the MOI increased. COS7 cells overexpressing K256E-α-actinin-4
showed UCHL1 protein upregulation versus uninfected and WT-α-
actinin-4 infected controls (Fig. 1G). Speciﬁcally, COS7 cells overex-
pressing K256E-α-actinin-4 at a MOI of 20, 50 and 100 show signif-
icant UCHL1 protein induction (by approximately 2-fold) as
compared to COS7 cells overexpressing WT-α-actinin-4 at equiva-
lent MOI (p b 0.01, p b 0.001 and p b 0.01, respectively) (Fig. 1H).
No differences in UCHL1 levels were observed in conditionally im-
mortalized human podocytes overexpressing either GFP, WT- or
K256E-α-actinin-4 and subjected to differential centrifugation,
suggesting that podocytes may behave differently in vitro (Fig. 1I).
Finally, to test whether UCHL1 upregulation results from increased
transcription, qPCR was performed and conﬁrmed no differencesin UCHL1 mRNA levels in renal and glomerular lysates of K256E-
ACTN4pod+/UCHL1+/+ mice (Fig. 1J and K), suggesting that
UCHL1 levels are increased post-translationally.
3.2. Development of UCHL1 knockout mice
In ACTN4-associated FSGS, UCHL1 inductionmay promote formation
of poly-ubiquitinated K256E-α-actinin-4 aggregates that choke the UPS
[11]. UCHL1 deletion is predicted to restore the UPS. To test this hypoth-
esis, we usedmice generated by Coulombe and Gray with global UCHL1
deletion (UCHL1−/−), where a selectable marker conferring neomycin
resistance was inserted within the catalytically essential 4th exon of
the mouse UCHL1 gene (Coulombe and Gray, in preparation). UCHL1
mRNA expression in renal cortex of nonTG/UCHL1+/+ mice was not
detected by qPCR in nonTG/UCHL1−/− mice (Fig. 2A). Furthermore,
UCHL1 protein levels were undetectable by western blot (Fig. 2B
and C) and immunohistochemistry (Fig. 2D) of renal cortex of
nonTG/UCHL1−/− mice, while nonTG/UCHL1+/+ exhibited some
detectable UCHL1. Similar to the phenotype observed with gad mice,
homozygous UCHL1 null mice show progressive neurodegeneration
that affects gait around 6–12 weeks of age. These mice are fertile,
although the females fail to care for pups, and are generally viable
for 6 months.
3.3. Albuminuria is reduced in K256E-ACTN4pod+/UCHL1−/− mice
K256E-ACTN4pod+/UCHL1+/+ mice were intercrossed with
UCHL1+/− mice to generate K256E-ACTN4pod+/UCHL1−/− mice.
Urinary albumin/creatinine ratios (ACR) were determined at 4 and
10 weeks of age. As previously reported, ~50% of K256E-ACTN4pod+/
UCHL1+/+ mice develop albuminuria at 4 weeks of age that is
maintained through 10 weeks of age. In this model, albuminuria cor-
relates with K256E-α-actinin-4 transgene mRNA levels [12]. nonTG/
UCHL1+/+ and nonTG/UCHL1−/− mice littermate controls were
not albuminuric. nonTG/UCHL1+/+ mice displayed mean ACR
values of 152 ± 11 μg/mg and 173 ± 30 μg/mg at 4 and 10 weeks
of age, respectively. Similarly, nonTG/UCHL1−/− mice displayed
mean ACR values of 131 ± 14 μg/mg and 107 ± 15 μg/mg at 4 and
10 weeks of age, respectively. In contrast, mean ACR values for
K256E-ACTN4pod+/UCHL1+/+ mice were elevated at 4 and 10 weeks
(2905 ± 1592 μg/mg and 2519 ± 1037 μg/mg). ACR levels for K256E-
ACTN4pod+/UCHL1−/−mice were also elevated in K256E-ACTN4pod+/
UCHL1+/+ mice at 4 weeks (4406 ± 2998 μg/mg). However, by
10 weeks, ACR values were signiﬁcantly reduced to 569 ± 131 μg/mg
for K256E-ACTN4pod+/UCHL1−/−mice (p b 0.01 vs. K256E-ACTN4pod/
UCHL1−/− mice mean ACR at 4 weeks of age) (Fig. 3A). Of note,
while the ACR levels of 4-week-old K256E-ACTN4pod+/UCHL1−/−
mice were greater than ACR levels of K256E-ACTN4pod+/UCHL1+/+
mice at 4 weeks, this difference was not statistically signiﬁcant. Similar
ﬁndings showing albuminuria amelioration in UCHL1 deleted mice
were obtained when urine samples were resolved by SDS-PAGE
(Fig. 3B). Plasma creatinine concentrations for nonTG/UCHL1+/+
and K256E-ACTN4pod+/UCHL1+/+ mice were determined to be
15.4 ± 1.3 and 16.2 ± 1.4 μM, respectively. Plasma creatinine levels
for nonTG/UCHL1−/− mice (14.2 ± 2.1 μM) were slightly higher
than the K256E-ACTN4pod+/UCHL1−/−mice (11.2 ± 0.7 μM), how-
ever no signiﬁcant statistical differences were determined between
all four mice groups (Fig. 3C).
3.4. Glomerular pathology and ﬁltration barrier damage are attenuated in
K256E-ACTN4pod+/UCHL1−/− mice
K256E-ACTN4pod+/UCHL1+/+mice present with characteristic his-
topathological features of FSGS that include glomerular scarring and
downstream tubular damage [12]. Indeed, analysis of PAS-stained
renal sections of 10-week-old mice conﬁrmed these ﬁndings.
Fig. 2. UCHL1 is absent from renal cortex of nonTG/UCHL1−/−mice. (A) qPCR reveals an amplicon migrating at ~300 bp, likely UCHL1mRNA (predicted amplicon size ~284 bp) in renal
cortex of nonTG/UCHL1+/+mice (lanes 1–3), that is absent in nonTG/UCHL1−/−mice (lanes 4 and 5). Control RNA from rodent, obtained commercially, served as a global control (lane
C). GAPDHmRNA served as an internal control. DNAmarkers (bp) are depicted in lane 0. (B–C)While the UCHL1 protein is detectable in nonTG/UCHL1+/+mice, western immunoblot-
ting and densitometry analysis reveals its absence in renal cortex of nonTG/UCHL1−/−mice (n = 3–4 per group). Differentiated human podocytes infected with adenovirus containing
a construct for K256E-α-actinin-4, to yield overexpression of K256E-α-actinin-4, served as a positive control for UCHL1 protein detection (+). β-Actin served as a loading control.
(D) Immunohistochemistry of UCHL1 conﬁrms its absence in glomeruli of nonTG/UCHL1−/−mice. UCHL1-positive cells are indicated in glomeruli of nonTG/UCHL1+/+mice by arrow-
heads (n = 3 per group). Magniﬁcation, 640×.
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lar and tubular damage, including tubular dilatation and accumula-
tion of proteinaceous casts [12]. K256E-ACTN4pod+/UCHL1−/−
mice showed evidence of attenuated glomerular injury and amelio-
rations in overall renal pathology (Fig. 4A, Supplemental Fig. 1).
Since the non-albuminuric K256E-ACTN4pod+/UCHL1+/+ mice do
not display histologic features of FSGS, only mice that exhibited
ACR N 500 μg/mg were selected for analysis. In K256E-ACTN4pod+/
UCHL1+/+ mice the proportion of healthy glomeruli was signiﬁ-
cantly reduced (33± 5%; p b 0.01) while the proportion of glomeruli
exhibiting segmental and global sclerosis was signiﬁcantly increased
(36 ± 4% and 31 ± 9%, respectively; p b 0.05) vs. nonTG/UCHL1+/+
mice. In contrast, K256E-ACTN4pod+/UCHL1−/−mice exhibited an ame-
liorated glomerular phenotype. Speciﬁcally, segmental and global
glomerulosclerosis were signiﬁcantly reduced (14 ± 4%; p b 0.05 and
17±9% of glomeruli, respectively), while 69± 9% of glomeruli exhib-
ited healthy histology (p b 0.01) as compared to K256E-ACTN4pod+/
UCHL1+/+ mice. N85% glomeruli were scored as healthy in nonTG/
UCHL1+/+ and nonTG/UCHL1−/−mice (Fig. 4B). A similar difference
was seen with relative glomerular tuft to the Bowman's capsule surface
area. K256E-ACTN4pod+/UCHL1+/+ mice showed a signiﬁcantly in-
creased surface area between the Bowman's capsule and the glomeru-
lar tuft (p b 0.05) as compared to nonTG/UCHL1+/+. This relative
area was normalized in K256E-ACTN4pod+/UCHL1−/− mice (p
b 0.05) (Fig. 4C). No signiﬁcant systolic blood pressure differences
were observed in nonTG/UCHL1+/+ (115 ± 5, 109 ± 3 and 112 ±
3 mm Hg at 6, 7 and 10 weeks) or nonTG/UCHL1−/−mice (106 ± 6,
106 ± 5 and 108± 2mmHg at 6, 7 and 10 weeks). However systolic
blood pressure was signiﬁcantly elevated in K256E-ACTN4pod+/
UCHL1+/+mice to 121 ± 5, 118 ± 6 and 118 ± 4 mm Hg at 6, 7 and
10 weeks of age respectively, vs. nonTG/UCHL1+/+mice (p b 0.001).
This elevation was attenuated in K256E-ACTN4pod+/UCHL1−/−mice to
112 ± 5, 112 ± 6 and 111 ± 4 mm Hg at the same time points (p
b 0.01 vs. K256E-ACTN4pod+/UCHL1+/+ mice) (Fig. 4D). Electron
microscopy analyses of K256E-ACTN4pod+/UCHL1+/+ mice glo-
meruli (ACR N 500 μg/mg) revealed signiﬁcant podocyte FP effacement
andGBM thickening, similar to previous observations [12] (Fig. 5A and B).
In fact, while nonTG/UCHL1+/+ and nonTG/UCHL1−/−mice showed
1.78 ± 0.05 and 1.76 ± 0.06 FP/μm GBM, K256E-ACTN4pod+/UCHL1+/+ mice exhibited a decrease to 0.69 ± 0.20 FP/μm GBM
(p b 0.01 vs. nonTG/UCHL1+/+ mice). Loss of UCHL1 in K256E-
ACTN4pod+/UCHL1−/−mice restored FP architecture as these exhib-
ited 1.48 ± 0.20 FP/μm GBM (p b 0.05 vs. K256E-ACTN4pod+/
UCHL1+/+ mice) (Fig. 5B and C). Additionally, GBM thickness was
signiﬁcantly increased in K256E-ACTN4pod+/UCHL1+/+mice to 290 ±
38 nm (p b 0.01 vs. nonTG/UCHL1+/+ mice) vs. 151 ± 0.39 nm
for nonTG/UCHL1+/+ and 150 ± 2.1 nm for nonTG/UCHL1−/−
mice. GBM thickening was signiﬁcantly reduced in K256E-ACTN4pod+/
UCHL1−/− mice to 185 ± 1.6 nm (p b 0.05 vs. K256E-ACTN4pod+/
UCHL1+/+mice) (Fig. 5B and D).
3.5. UCHL1 expression positively correlated with poly-ubiquitinated
proteins but negatively correlated with K256E-α-actinin-4
In vitro data show that UCHL1 levels positively correlate with Ub
expression, suggesting that UCHL1 may in fact fuel the UPS and acti-
vate protein degradation [16]. Since UCHL1 is increased in ACTN4-
associated FSGS, we tested whether increased UCHL1 in glomeruli
of K256E-ACTN4pod+/UCHL1+/+ mice correlated with increased
Ub levels. Immunoblotting for Ub revealed slightly elevated levels
of renal poly-ubiquitinated proteins in K256E-ACTN4pod+/UCHL1+/+
mice renal lysates vs. nonTG/UCHL1+/+ mice. In contrast,
K256E-ACTN4pod+/UCHL1−/− mice exhibited signiﬁcantly re-
duced (p b 0.05) renal ubiquitinated protein levels (Fig. 6A and B). Ac-
cordingly, immunoblotting for HA-tagged K256E-α-actinin-4 revealed
increased levels in K256E-ACTN4pod+/UCHL1−/− mice as compared
to K256E-ACTN4pod+/UCHL1+/+ mice (p b 0.05), suggesting K256E-
α-actinin-4 aggregate accumulation and UPS impairment when
UCHL1 is absent (Fig. 6C and D). Interestingly, while increased poly-
Ub content is consistent with UPS failure, the decreased K256E-α-
actinin-4 levels in podocytes of K256E-ACTN4pod+/UCHL1+/+ mice
suggest an activated UPS. Conversely, the decreased Ub content in addi-
tion to increased K256E-α-actinin-4 levels suggests decreased UPS ac-
tivity in K256E-ACTN4pod+/UCHL1−/−mice. Since K256E-α-actinin-4
levels are increased in K256E-ACTN4pod+/UCHL1−/−mice, we sought
to determine if this increase correlated with changes in K256E-α-
actinin-4/actin aggregation. To test if our ﬁndings were reproducible
in vitro, we used differentiated conditionally immortalized human
Fig. 3. Reduced albuminuria in K256E-ACTN4pod+/UCHL1−/−mice. (A) Urinary albumin levels, normalized to creatinine contentwere elevated in a subset of K256E-ACTN4pod+/UCHL1+/+
mice (n= 18) at 4 and 10 weeks of age. While urinary albumin/creatinine ratios (ACR) were elevated in K256E-ACTN4pod+/UCHL1−/−mice at 4 weeks of age, these were attenuated sig-
niﬁcantly by 10 weeks (n=13; p b 0.01 vs. K256E-ACTN4pod+/UCHL1−/−mice ACR at 4 weeks). No signiﬁcant changeswere observed for nonTG/UCHL1+/+and nonTG/UCHL1−/−mice
between 4 and 10 weeks of age, n = 19 and n = 16, respectively. (B) Coomassie Brilliant Blue staining of urine samples processed by SDS-PAGE indicates an intense band migrating at
~67 kDa (likely albumin) in K256E-ACTN4pod+/UCHL1+/+mice which is reduced in samples obtained from K256E-ACTN4pod+/UCHL1−/−mice at 10 weeks (n= 3 per group). Molecular
weightmarkers (kDa) are depicted in lane 1while standard concentrations (μg) of bovine serum albumin (BSA) are depicted in lanes 2 and 3. (C) Plasma creatinine concentrations were not
signiﬁcantly different between mice groups at 10 weeks of age (n = 5 per group).
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siRNA oligonucleotides. We ﬁrst determined by western immuno-
blotting that 2.5 and 5 nM of UCHL1 siRNA yielded optimal
knockdown of UCHL1 levels in podocytes (Fig. 6E). Choosing
2.5 nM as the optimal dose for UCHL1 knockdown, we pursued co-
infection/transfection experiments in podocytes overexpressing
K256E-α-actinin-4 or WT-α-actinin-4 and determined whether
knocking down UCHL1 levels impacted the expression of K256E-α-
actinin-4. Western immunoblotting revealed no signiﬁcant changes
in the expression of both WT- and K256E-α-actinin-4 (Fig. 6F).
While the expression pattern of K256E-α-actinin-4 remained un-
changed following UCHL1 knockdown, we tested whether the aggre-
gation of K256E-α-actinin-4 was affected. Differential centrifugation
experiments revealed no changes in the distribution of K256E-α-
actinin-4. Speciﬁcally, K256E-α-actinin-4 remained associated with
the triton-insoluble (TI) fraction as compared to the triton-soluble
(TS) fraction following incubation with both scrambled and UCHL1
siRNA oligonucleotides, suggesting that K256E-α-actinin-4 aggrega-
tion/association with large cytoskeletal fragments was unaffected by
UCHL1 knockdown. The distribution ofWT-α-actinin-4 remained asso-
ciated with the TS fraction even following UCHL1 knockdown. WT-α-
actinin-4 TS/TI fraction distribution remained greater in scrambled
and UCHL1 siRNA transfected conditions versus K256E-α-actinin-4
scrambled and UCHL1 siRNA transfected podocytes (p b 0.001)(Fig. 6G and H). Similarly, immunoﬂuorescence of podocytes overex-
pressing K256E-α-actinin-4 + UCHL1 knockdown and subjected to
10% equibiaxial stretch for 24 h conﬁrmed no differences in K256E-
α-actinin-4 aggregation as compared to scrambled controls (data
not shown).
3.6. Tubular and glomerular cell apoptosis are decreased in K256E-
ACTN4pod+/UCHL1−/− mice
K256E-α-actinin-4 aggregation and misfolding lead to cytotoxicity
and apoptosis [11]. Accordingly, enhanced UCHL1 expression stabilizes
Ub levels, thereby over-fuelling the UPS, andwould be predicted to lead
to cellular stress and apoptosis. We therefore assayed for apoptosis fol-
lowing UCHL1 deletion in ACTN4-associated FSGS. TUNEL staining of
renal sections revealed increased TUNEL-positive tubular nuclei
per section (183 ± 41) in K256E-ACTN4pod+/UCHL1+/+ mice
(p b 0.01 vs. nonTG/UCHL1+/+ mice). The increase was partly
attenuated to 98 ± 26 TUNEL-positive tubular nuclei per section
in K256E-ACTN4pod+/UCHL1−/−mice (p b 0.05 vs. K256E-ACTN4pod+/
UCHL1+/+ mice). nonTG/UCHL1+/+ and nonTG/UCHL1−/− mice
displayed b50 TUNEL-positive tubular cells per section (Fig. 7A
and B). Similarly, TUNEL staining revealed a 24 ± 6% induction in
TUNEL-positive nuclei per glomerular section in K256E-ACTN4pod+/
UCHL1+/+mice (p b 0.01 vs. nonTG/UCHL1+/+mice). The increase
Fig. 4.Glomerulosclerosis is attenuated inK256E-ACTN4pod+/UCHL1−/−mice. (A) A representative PAS-stained glomerular section (upper panel) and renal cortical section (lower panel)
of a 10-week-old mouse from each mouse group. PAS stained sections indicate widespread renal pathology in 10-week-old K256E-ACTN4pod+/UCHL1+/+ mice, consisting of
glomerulosclerosis, proteinaceous casts (arrowhead) and tubular dilatation (arrow). Tubulointerstitial damage was less frequent in K256E-ACTN4pod+/UCHL1−/−mice. Magniﬁcation,
640× (upper panel) and 200× (lower panel). (B) Glomerular scoring reveals a reduced proportion of healthy glomeruli (p b 0.001 vs. nonTG/UCHL1+/+mice) and an increased propor-
tion of segmental (p b 0.05 vs. nonTG/UCHL1+/+mice) and globally sclerotic (p b 0.05 vs. nonTG/UCHL1+/+mice) glomeruli in K256E-ACTN4pod+/UCHL1+/+mice. K256E-ACTN4pod+/
UCHL1−/− mice displayed an increased proportion of healthy (p b 0.01) and a decreased proportion of segmental (p b 0.05) and global sclerotic glomeruli vs. K256E-ACTN4pod+/
UCHL1+/+mice. A minimum of 60 glomeruli were analyzed per mouse (n = 5 per group). (C) The relative difference between the Bowman's capsule area and the glomerular
tuft area is increased in K256E-ACTN4pod+/UCHL1+/+mice at 10 weeks (n=8; p b 0.05 vs. nonTG/UCHL1+/+mice) and normalized in K256E-ACTN4pod+/UCHL1−/−mice (n = 8;
p b 0.05 vs. K256E-ACTN4pod+/UCHL1+/+ mice). n = 10 and n = 9 for nonTG/UCHL1+/+ and nonTG/UCHL1−/− mice, respectively. (D) Systolic blood pressure is in-
creased in K256E-ACTN4pod+/UCHL1+/+mice (n = 7; p b 0.001 vs. nonTG/UCHL1+/+ mice) at 6, 7 and 10 weeks of age. This increase is attenuated in K256E-ACTN4pod+/
UCHL1−/− mice (n = 8; p b 0.01 vs. K256E-ACTN4pod+/UCHL1+/+ mice). n = 7 and n = 9 for nonTG/UCHL1+/+ and nonTG/UCHL1−/− mice respectively.
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1% in K256E-ACTN4pod+/UCHL1−/− mice (p b 0.01 vs. K256E-
ACTN4pod+/UCHL1+/+ mice). Both nonTG/UCHL1+/+ and nonTG/
UCHL1−/− mice displayed b8% of TUNEL-positive glomerular cells
per glomerular section (Fig. 7C and D). Interestingly, K256E-ACTN4pod+/UCHL1+/+ mice showed no differences in WT1-
positive nuclei per glomerulus in comparison to nonTG/UCHL1+/+
mice controls. In fact, no signiﬁcant differences were observed for
all four mice groups, suggesting that the glomerular apoptosis in
K256E-ACTN4pod+/UCHL1+/+ mice is not podocyte-speciﬁc (Fig. 8).
Fig. 5. Foot process effacement is ameliorated in K256E-ACTN4pod+/UCHL1−/−mice. (A) Electron microscopy reveals foot process (FP) effacement and some irregular glomerular base-
mentmembrane (GBM)blebbing (arrowhead) in K256E-ACTN4pod+/UCHL1+/+mice at 10 weeks. FP architecture appears relatively intact in K256E-ACTN4pod+/UCHL1−/−mice (n=3
per group). Scale bar represents 2 μm. (B)Representativemicrographsdepicting areas of severe podocyte FP effacement (arrowhead, upper left panel) andGBMthickening (asterisk, lower
left panel) in 10-week-old K256E-ACTN4pod+/UCHL1+/+mice which are attenuated in K256E-ACTN4pod+/UCHL1−/−mice (upper and lower right panels). Scale bar represents 500 nm.
n= 3 per group (C) Graph depicting the number of podocyte FP per micron of GBM length. The number of FP per GBM length were signiﬁcantly decreased in K256E-ACTN4pod+/UCHL1+/+
mice (p b 0.01) vs. nonTG/UCHL1+/+mice. The decrease in FP per GBM lengthwas attenuated in K256E-ACTN4pod+/UCHL1−/−mice (p b 0.05 vs. K256E-ACTN4pod+/UCHL1+/+mice). 2–3
glomeruli were analyzed per group. (D) Graph depicting GBMwidth, where K256E-ACTN4pod+/UCHL1+/+mice exhibited a signiﬁcant increase in GBMwidth (p b 0.01) vs. nonTG/UCHL1+/
+mice controls. K256E-ACTN4pod+/UCHL1−/−mice exhibit a relatively normalized GBMwidth (p b 0.05) vs. K256E-ACTN4pod+/UCHL1+/+mice. 2–3 glomeruli were analyzed per group.
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In our mouse model of ACTN4-associated FSGS, UCHL1 expression
was increased in podocytes. UCHL1 deletion ameliorated the renal phe-
notype, indicating that its activitymay play a detrimental role in the eti-
ology of this FSGS model.
The K256E mutation imposes a conformational change on the α-
actinin-4 molecule leading to cytotoxic α-actinin-4/actin aggregate
formation. Nonetheless, K256E-α-actinin-4 is a rapidly degraded cyto-
skeletal protein with a half-life of 15 h, as compared to wt-α-actinin-
4, which has a half-life N30 h [5,8–10]. In ACTN4-associated FSGS,
UCHL1 induction may serve to fuel the UPS to help eliminate K256E-
α-actinin-4. In contrast to ﬁndings in other glomerular disease modelsthat show an inverse correlation between UCHL1 expression and pro-
teasome activity, our ﬁndings suggest that UCHL1 expression positively
correlates with proteasome activity as K256E-α-actinin-4 levels were
signiﬁcantly lower in podocytes of K256E-ACTN4pod+/UCHL1+/+
mice as compared to K256E-ACTN4pod+/UCHL1−/−mice. Interestingly,
UPS impairment in podocytes of UCHL1 knockout mice resembles the
phenotype observed in gadmice, where UPS impairment and protein
inclusions have been described [19,25].
In light of our ﬁndings we postulate the following: In the absence
of UCHL1, monomeric Ub levels are signiﬁcantly reduced thereby
diminishing K256E-α-actinin-4 poly-ubiquitination and degradation
via the UPS. Over time however, the K256E-α-actinin-4 protein will
form aggregates despite the absence of UCHL1. Without sufﬁcient
Fig. 6. UCHL1 expression positively correlated with poly-ubiquitinated protein levels but negatively correlated with K256E-α-actinin-4 levels. (A) Representative immunoblot showing
poly-ubiquitinated proteins in renal cortical lysates of eachmouse group at 10 weeks of age. (B) Graph depicting slightly elevated poly-ubiquitinated protein levels in K256E-ACTN4pod+/
UCHL1+/+mice as determined by densitometry. Poly-ubiquitinated proteins are signiﬁcantly reduced inK256E-ACTN4pod+/UCHL1−/−mice (p b 0.05 vs. K256E-ACTN4pod+/UCHL1+/+
mice). (C) Representative immunoblot showing HA-tagged K256E-α-actinin-4 levels in renal cortical lysates of eachmouse group at 10 weeks of age. (D) Graph depicting decreased HA-
tagged K256E-α-actinin-4 levels in K256E-ACTN4pod+/UCHL1+/+mice as compared to K256E-ACTN4pod+/UCHL1−/− mice which exhibit signiﬁcantly elevated levels of HA-tagged
K256E-α-actinin-4 levels (p b 0.05) (n = 3 per group). (E) A 72-hour UCHL1 siRNA dose course in human podocytes showing optimal UCHL1 knockdown between 2.5 and 5 nM of
UCHL1 siRNA as compared to scrambled siRNA-treated controls (n = 4). (F) Human podocytes overexpressing K256E-α-actinin-4 (MOI = 30) and treated with 2.5 nM UCHL1 siRNA
for 72 h showed no differences in HA-tagged K256E-α-actinin-4 versus scrambled (scr) controls. A slight decrease was observed in levels ofWT-α-actinin-4 in human podocytes treated
with UCHL1 siRNA but this was not signiﬁcant. (G) A representative immunoblot showing the distribution of either HA-taggedWT- or K256E-α-actinin-4 in WT- or K256E-α-actinin-4
overexpressing human podocytes (MOI= 30) and transfectedwith UCHL1 siRNA (2.5 nM) and subjected to differential centrifugation. I, TI and TS represent the input, triton-soluble and
triton-insoluble isolated fractions. (H) Densitometry conﬁrms decreased K256E-α-actinin-4 in the TS relative to the TI cellular fractions of human podocytes overexpressing K256E-α-
actinin-4 and transfected with UCHL1 siRNA. No differences were observed compared to scrambled controls. Conversely, human podocytes overexpressing WT-α-actinin-4 and
transfected with UCHL1 siRNA, WT-α-actinin-4 was mainly distributed to the TS fraction versus the TI fraction. No differences were observed as compared to scrambled controls. WT-
α-actinin-4 transfected with either scrambled or UCHL1 siRNA showed signiﬁcantly increased WT-α-actinin-4 levels in the TS fraction as compared to K256E-α-actinin-4 expressing
human podocytes treated with scrambled or UCHL1 siRNA, respectively (p b 0.001). β-Actin served as a loading control for all western blots.
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this mutant protein will form aggregates that choke the proteasome
in podocytes of K256E-ACTN4pod+/UCHL1−/−mice. Our in vitro results
are consistent with this hypothesis in that mutant α-actinin-4 con-
tinues to associate with large cytoskeletal fragments (i.e., TI fraction)
regardless of UCHL1 expression in conditionally immortalized
human podocytes. In contrast, if UCHL1 upregulation promotes pro-
teolysis in K256E-ACTN4pod+/UCHL1+/+ mice, K256E-α-actinin-4
aggregates can be degraded via the UPS. While K256E-α-actinin-4
degradation should be beneﬁcial in relieving podocyte cytotoxicity,
the histopathological and albuminuria data do not correspond to an
ameliorated phenotype in K256E-ACTN4pod+/UCHL1+/+ mice. In fact,
since K256E-α-actinin-4 can heterodimerize with wt-α-actinin-4
(in addition to homodimerizing to itself) both K256E- and wt-α-
actinin-4 can be degraded by the proteasome in heterodimeric
form [10]. As a result, the cytoskeleton of podocytes from K256E-ACTN4pod+/UCHL1+/+ mice would resemble that of an α-actinin-4
deﬁcient podocyte [6,10]. In fact, α-actinin-4 knockout mice develop
podocyte FP effacement, proteinuria and glomerular disease, similar
to K256E-ACTN4pod+/UCHL1+/+ mice [6]. Conversely, UPS impair-
ment in K256E-ACTN4pod+/UCHL1−/−mice would preserve mutant
and wt-α-actinin-4 expression, thereby partially stabilizing the cy-
toskeleton. This might explain why albuminuria in K256E-
ACTN4pod+/UCHL1−/− mice is initially elevated at 4 weeks of age,
but was signiﬁcantly decreased by 10 weeks of age. Furthermore,
K256E-ACTN4pod+/UCHL1−/−mice may not develop the same degree
of ﬁltration barrier injury as K256E-ACTN4pod+/UCHL1+/+mice, limit-
ing FP fusion and the development of FSGS lesions.
Interestingly, conditionally immortalized human podocytes overex-
pressing K256E-α-actinin-4 do not exhibit signiﬁcant increases in
UCHL1 protein levels as compared to WT-α-actinin-4 and GFP overex-
pressing podocyte controls. In fact, since Meyer-Schweisinger et al.
Fig. 7. Tubular and glomerular cell apoptosis are decreased in K256E-ACTN4pod+/UCHL1−/−mice. (A) Representative images of renal cortex for each mouse group revealing TUNEL-
positive nuclei in tubules (arrowheads). Magniﬁcation, 640×. (B) Graph depicting the total number of TUNEL-positive tubular nuclei per renal section in 10-week-old mice. Tubular
TUNEL-positive nuclei numbers were increased in K256E-ACTN4pod+/UCHL1+/+mice (n = 6; p b 0.01 vs. nonTG/UCHL1+/+ mice) and decreased in K256E-ACTN4pod+/UCHL1−/−
mice (n= 5; p b 0.05 vs. K256E-ACTN4pod+/UCHL1+/+mice). n = 5 for nonTG/UCHL1+/+ and nonTG/UCHL1−/−mice. (C) Representative glomeruli showing TUNEL-positive nuclei
(arrowhead) in 10-week old mice. Magniﬁcation, 640×. (D) Graph depicts the number of TUNEL-positive nuclei per glomerulus. The number of glomerular TUNEL-positive nuclei was
elevated in K256E-ACTN4pod+/UCHL1+/+ mice (n = 6; p b 0.01 vs. nonTG/UCHL1+/+ mice) and decreased in K256E-ACTN4pod+/UCHL1−/− mice (n = 5; p b 0.01 vs. K256E-
ACTN4pod+/UCHL1+/+mice). n = 5 for nonTG/UCHL1+/+ and nonTG/UCHL1−/−mice. A minimum of 20 glomeruli were analyzed per mouse.
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ferentiation status of conditionally immortalized human podocytes, we
compared UCHL1 protein levels in undifferentiated and differentiated
human podocytes [13]. We found no differences in UCHL1 expression,
regardless of podocyte differentiation status (veriﬁed by immunoblot-
ting with anti-synaptopodin) (data not shown), suggesting that
UCHL1 levels are consistently elevated in our conditionally immortal-
ized human podocyte cell line. We reproduced these experiments in
conditionally immortalized mouse podocytes and observed similar
ﬁndings (data not shown). Therefore, the presence of K256E-α-
actinin-4 in our cultured human podocytes may not have been sufﬁ-
cient to further upregulate UCHL1 levels, given that UCHL1 levels
were initially elevated. Conversely, the presence of K256E-α-
actinin-4 in K256E-ACTN4pod+/UCHL1+/+ mice lead to UCHL1 up-
regulation, suggesting that cultured podocytes lose some of the char-
acteristics that they exhibit in vivo [26,27]. We therefore undertook
UCHL1 silencing-based approaches in human podocytes overex-
pressing K256E-α-actinin-4 to better model our ﬁndings in vivo. Inaddition, we overexpressed K256E-α-actinin-4 in COS7 cells and
observed UCHL1 upregulation conﬁrming that K256E-α-actinin-4
can lead to UCHL1 upregulation in other cell types in vitro.
The blood pressure elevation (~10 mm Hg) in K256E-ACTN4pod+/
UCHL1+/+ mice corresponds to previous ﬁndings by Michaud et al.
(2006) and on initial analysis, may be a result secondary to compro-
mised ﬁltration barrier integrity along with downstream tubular dam-
age, leading to activation of the renin–angiotensin–aldosterone system
(RAAS). However, non-albuminuric mice also show blood pressure ele-
vations without the histopathological features of FSGS thereby refuting
this hypothesis [12]. Furthermore, increased aldosterone production
may lead to edema which would likely result in blood pressure eleva-
tions. However, no signiﬁcant body weight changes were observed for
all four mice groups, suggesting that K256E-ACTN4pod+/UCHL1+/+
mice are not edemic (data not shown). As such, we cannot conclusively
determine a role for the RAAS in the context of blood pressure elevation
in K256E-ACTN4pod+/UCHL1+/+ mice. The blood pressure normaliza-
tion in K256E-ACTN4pod+/UCHL1−/− mice may in fact be regulated
Fig. 8.WT1-positive nuclei are unchanged in all mice groups. (A) Glomerular sections of 10-week-oldmice representative of eachmouse group, depicting immunoreactiveWT1-positive
nuclei. Magniﬁcation, 200×. (B) Graph representing the number of WT1-positive nuclei per glomerular section, which was not signiﬁcantly different between mouse groups. n = 3 per
group and a minimum of 20 glomeruli were analyzed per mouse.
1039N.C. Read et al. / Biochimica et Biophysica Acta 1842 (2014) 1028–1040through other mechanisms related speciﬁcally to the nature of the
UCHL1 null phenotype.
While UCHL1 has a long half-life (48 h) and its expression is largely
regulated by macroautophagy [28], it can also be degraded by the UPS
[29]. Our ﬁndings suggest that UCHL1 may be induced through other
regulators, such as NFκB, which may be increased in this diseased set-
ting [30]. Moreover, we cannot rule out the possibility that reduced pro-
moter methylation, which normally silences UCHL1 expression in non-
neuronal tissues, underlies the FSGS-associated induction [31]. While
the speciﬁc triggers that lead to increasedUCHL1 expression and its pre-
cise enzymatic function(s) remain unclear, our data strongly support
the notion that UCHL1 carries out a detrimental role in FSGS lesion de-
velopment in ACTN4-associated FSGS, as supported by the ameliorated
phenotype of K256E-ACTN4pod+/UCHL1−/−mice.
In summary, UCHL1 is expressed in podocytes of K256E-ACTN4pod+/
UCHL1+/+mice. UCHL1 deletion in ACTN4-associated FSGS reduced
albuminuria, glomerulosclerosis, FP effacement, GBM thickening,
glomerular and tubular cell apoptosis, and ameliorated the overall
renal pathology. These observations coincide with decreased poly-
ubiquitinated protein levels and increased K256E-α-actinin-4 levels
in K256E-ACTN4pod+/UCHL1−/−mice kidneys, suggesting impaired
proteolysis of K256E-α-actinin-4. As a result, endogenousα-actinin-
4 may be protected from degradation, preserving the podocyte's
architectural integrity and improving glomerular function.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.03.009.
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